- Home
- WRBY vs ZLAB Comparison
WRBY vs ZLAB Comparison
Compare WRBY & ZLAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WRBY
- ZLAB
- Stock Information
- Founded
- WRBY 2010
- ZLAB 2013
- Country
- WRBY United States
- ZLAB China
- Employees
- WRBY N/A
- ZLAB N/A
- Industry
- WRBY Ophthalmic Goods
- ZLAB Biotechnology: Pharmaceutical Preparations
- Sector
- WRBY Health Care
- ZLAB Health Care
- Exchange
- WRBY Nasdaq
- ZLAB Nasdaq
- Market Cap
- WRBY 3.1B
- ZLAB 3.0B
- IPO Year
- WRBY 2021
- ZLAB 2017
- Fundamental
- Price
- WRBY $26.61
- ZLAB $27.22
- Analyst Decision
- WRBY Buy
- ZLAB Strong Buy
- Analyst Count
- WRBY 11
- ZLAB 3
- Target Price
- WRBY $22.00
- ZLAB $55.00
- AVG Volume (30 Days)
- WRBY 1.6M
- ZLAB 603.6K
- Earning Date
- WRBY 02-26-2025
- ZLAB 02-27-2025
- Dividend Yield
- WRBY N/A
- ZLAB N/A
- EPS Growth
- WRBY N/A
- ZLAB N/A
- EPS
- WRBY N/A
- ZLAB N/A
- Revenue
- WRBY $742,527,000.00
- ZLAB $355,748,000.00
- Revenue This Year
- WRBY $16.92
- ZLAB $49.04
- Revenue Next Year
- WRBY $13.10
- ZLAB $46.80
- P/E Ratio
- WRBY N/A
- ZLAB N/A
- Revenue Growth
- WRBY 13.47
- ZLAB 35.01
- 52 Week Low
- WRBY $11.35
- ZLAB $13.48
- 52 Week High
- WRBY $28.68
- ZLAB $36.60
- Technical
- Relative Strength Index (RSI)
- WRBY 55.19
- ZLAB 51.88
- Support Level
- WRBY $25.80
- ZLAB $26.37
- Resistance Level
- WRBY $28.68
- ZLAB $28.24
- Average True Range (ATR)
- WRBY 1.20
- ZLAB 1.30
- MACD
- WRBY 0.00
- ZLAB 0.21
- Stochastic Oscillator
- WRBY 56.76
- ZLAB 65.12
About WRBY Warby Parker Inc.
Warby Parker Inc is engaged in designing and developing designer prescription glasses and contacts, and providing the facility of eye exams and vision tests. The company predominantly derives revenue from the sales of eyewear products, optical services, and accessories. The firm sells products and services through its stores, website, and mobile apps. Revenue generated from eyewear products includes the sales of prescription and non-prescription optical glasses and sunglasses, contact lenses, eyewear accessories, and expedited shipping charges.
About ZLAB Zai Lab Limited
Zai Lab Ltd is a biopharmaceutical company focusing on discovering or licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need including in the fields of oncology, autoimmune and infectious diseases. The pipeline of proprietary drug candidates of the company includes ZL-2306 for treatments across multiple solid tumor types including ovarian and certain types of breast and lung cancers; ZL-2401 which is an antibiotic in a new class of tetracycline derivatives; and ZL-2301 is an oral, small molecule which targets HCC.